A Randomized, Open-label, Single Dose, Two-way Crossover Phase 1 Study to Evaluate the Pharmacokinetics and Safety of "BR1016C" With "BR1016D" in Healthy Volunteers
Latest Information Update: 26 May 2023
At a glance
- Drugs BR 1016C (Primary)
- Indications Chronic heart failure
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 22 May 2023 Status changed from recruiting to completed.
- 08 Nov 2021 New trial record